SG11201506651SA - Vortioxetine manufacturing process - Google Patents

Vortioxetine manufacturing process

Info

Publication number
SG11201506651SA
SG11201506651SA SG11201506651SA SG11201506651SA SG11201506651SA SG 11201506651S A SG11201506651S A SG 11201506651SA SG 11201506651S A SG11201506651S A SG 11201506651SA SG 11201506651S A SG11201506651S A SG 11201506651SA SG 11201506651S A SG11201506651S A SG 11201506651SA
Authority
SG
Singapore
Prior art keywords
vortioxetine
manufacturing process
manufacturing
vortioxetine manufacturing
Prior art date
Application number
SG11201506651SA
Other languages
English (en)
Inventor
Thomas Ruhland
Kim Lasse Christensen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SG11201506651SA publication Critical patent/SG11201506651SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02Iron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG11201506651SA 2013-02-22 2014-02-20 Vortioxetine manufacturing process SG11201506651SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361767883P 2013-02-22 2013-02-22
DKPA201300104 2013-02-22
PCT/EP2014/053313 WO2014128207A1 (en) 2013-02-22 2014-02-20 Vortioxetine manufacturing process

Publications (1)

Publication Number Publication Date
SG11201506651SA true SG11201506651SA (en) 2015-09-29

Family

ID=59215387

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506651SA SG11201506651SA (en) 2013-02-22 2014-02-20 Vortioxetine manufacturing process

Country Status (37)

Country Link
US (1) US9353073B2 (enExample)
EP (1) EP2958903B1 (enExample)
JP (1) JP6464098B2 (enExample)
KR (1) KR102230628B1 (enExample)
CN (1) CN104995181B (enExample)
AP (1) AP2015008640A0 (enExample)
AU (1) AU2014220735B2 (enExample)
BR (1) BR112015019268B1 (enExample)
CA (1) CA2901821A1 (enExample)
CL (1) CL2015002309A1 (enExample)
CR (1) CR20150423A (enExample)
CY (1) CY1118883T1 (enExample)
DK (1) DK2958903T3 (enExample)
DO (1) DOP2015000187A (enExample)
EA (1) EA027756B1 (enExample)
ES (1) ES2625380T3 (enExample)
GE (1) GEP201706749B (enExample)
HR (1) HRP20170607T1 (enExample)
IL (1) IL240501B (enExample)
LT (1) LT2958903T (enExample)
MA (1) MA38338B1 (enExample)
ME (1) ME02671B (enExample)
MX (1) MX362355B (enExample)
MY (1) MY172337A (enExample)
PE (1) PE20151589A1 (enExample)
PH (1) PH12015501807B1 (enExample)
PL (1) PL2958903T3 (enExample)
PT (1) PT2958903T (enExample)
RS (1) RS55932B1 (enExample)
RU (1) RU2652265C2 (enExample)
SG (1) SG11201506651SA (enExample)
SI (1) SI2958903T1 (enExample)
SM (1) SMT201700238T1 (enExample)
TN (1) TN2015000335A1 (enExample)
UA (1) UA116236C2 (enExample)
WO (1) WO2014128207A1 (enExample)
ZA (1) ZA201506050B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3311666T (pt) 2010-08-18 2021-06-21 Biosplice Therapeutics Inc Dicetonas e hidroxicetonas como ativadores da via de sinalização de catenina
SG10201606032VA (en) 2013-02-22 2016-09-29 Samumed Llc Gamma-Diketones As Wnt/Beta -Catenin Signaling Pathway Activators
CN107106549B (zh) 2014-08-20 2020-06-16 萨穆梅德有限公司 用于治疗和预防老化皮肤和皱纹的γ–二酮
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
WO2016151328A1 (en) 2015-03-26 2016-09-29 Cipla Limited Method for making serotonin reuptake inhibitors
CN106279065A (zh) * 2015-05-12 2017-01-04 北京深蓝海生物医药科技有限公司 一种氢溴酸沃替西汀的精制转晶方法
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
WO2017137048A1 (en) * 2016-02-08 2017-08-17 H. Lundbeck A/S Synthesis of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN109912538B (zh) * 2019-01-22 2021-03-12 安徽赛乐普制药有限公司 一种抗抑郁药沃替西汀的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CA2467118A1 (en) * 2001-12-20 2003-07-03 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
EP2439201B1 (en) * 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
HRP20170607T1 (hr) 2017-06-30
JP6464098B2 (ja) 2019-02-06
PE20151589A1 (es) 2015-12-03
DOP2015000187A (es) 2015-11-30
PL2958903T3 (pl) 2017-08-31
EA027756B1 (ru) 2017-08-31
CY1118883T1 (el) 2018-01-10
MX362355B (es) 2019-01-14
CL2015002309A1 (es) 2016-03-04
PH12015501807A1 (en) 2015-11-09
AU2014220735A1 (en) 2015-08-20
LT2958903T (lt) 2017-08-25
MA38338B1 (fr) 2018-10-31
RU2652265C2 (ru) 2018-04-27
CR20150423A (es) 2015-10-20
PT2958903T (pt) 2017-05-26
TN2015000335A1 (en) 2017-01-03
KR20150118146A (ko) 2015-10-21
SI2958903T1 (sl) 2017-09-29
JP2016509042A (ja) 2016-03-24
ES2625380T3 (es) 2017-07-19
RU2015134407A (ru) 2017-03-28
PH12015501807B1 (en) 2019-05-31
CN104995181A (zh) 2015-10-21
CA2901821A1 (en) 2014-08-28
BR112015019268B1 (pt) 2023-01-10
KR102230628B1 (ko) 2021-03-22
HK1216098A1 (en) 2016-10-14
MX2015010656A (es) 2015-12-17
RS55932B1 (sr) 2017-09-29
GEP201706749B (en) 2017-10-10
DK2958903T3 (en) 2017-05-15
SMT201700238T1 (it) 2017-07-18
EA201591349A1 (ru) 2015-12-30
CN104995181B (zh) 2017-03-08
IL240501A0 (en) 2015-09-24
EP2958903B1 (en) 2017-04-12
ZA201506050B (en) 2017-08-30
EP2958903A1 (en) 2015-12-30
US9353073B2 (en) 2016-05-31
AP2015008640A0 (en) 2015-08-31
ME02671B (me) 2017-06-20
AU2014220735B2 (en) 2017-06-22
MA38338A1 (fr) 2016-09-30
US20160009670A1 (en) 2016-01-14
IL240501B (en) 2018-08-30
UA116236C2 (uk) 2018-02-26
BR112015019268A2 (pt) 2020-01-28
WO2014128207A1 (en) 2014-08-28
MY172337A (en) 2019-11-21

Similar Documents

Publication Publication Date Title
GB2520596B (en) Manufacturing method
GB201321440D0 (en) Process
GB201312991D0 (en) Process
ZA201506050B (en) Vortioxetine manufacturing process
GB201307334D0 (en) Process
GB201416005D0 (en) Process
GB201421426D0 (en) Process
GB201421428D0 (en) Process
GB201322454D0 (en) Process
GB201318888D0 (en) Process
GB201401963D0 (en) Process
GB201401922D0 (en) Process
GB201322273D0 (en) Process
GB201320869D0 (en) Process
GB201314334D0 (en) Process
GB201307327D0 (en) Process
GB201302441D0 (en) Process
IL239449A0 (en) process
GB201316253D0 (en) Process
GB201307951D0 (en) Process
GB2520796B (en) Process
GB201323151D0 (en) Process
GB201418099D0 (en) Process
GB201303604D0 (en) Manufacturing process
GB201319357D0 (en) Process